Isomorphic Labs is reimagining drug discovery with the power of AI, and we’re scaling our ML team to support the rapid growth of our best-in-class AI models.Heading to ICML and want to find out more? Register to connect with some of our ML team at ICML between 13-19 July: https://t.co/nJaWaAq0XkBe sure to catch a talk by @_lychrel and @benrozemberczki Isomorphic Labs: Towards a System for Rational Drug Design with AI#ICML2025 ...

AI在药物发现领域的应用 - Google DeepMind 和 Isomorphic Labs 正在利用 AI 赋能人类专家，探索广阔的分子空间 [1] - AI 代理被用于药物发现，预示着该领域未来的发展方向 [1]

We are thrilled to support the UK’s new #OpenBind consortium, a government-backed initiative to create the world’s largest open dataset for AI drug discovery. ...

AI in Drug Discovery - Isomorphic Labs 致力于从根本上重新思考药物发现，利用人工智能技术 [1] - 该公司正在探索人工智能在应对疾病方面的可能性 [1] - 讨论了人工智能在生物学中的应用 [1] - 重点介绍了 AlphaFold 3 在药物发现中的作用 [1] Future of Drug Development - 探讨了人机协作在药物设计中的应用 [2] - 讨论了药物设计面临的挑战 [2] - 探索了超越动物模型的药物研发方法 [2] - 展望了人工智能药物的未来 [2]

Core Insights - Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) are leading the integration of artificial intelligence in drug discovery, aiming to transform the biotech sector by improving efficiency and reducing costs [1][2][3] Company Overview Recursion Pharmaceuticals (RXRX) - RXRX utilizes its AI-driven platform, Recursion OS, in collaboration with NVIDIA to enhance drug discovery processes [5] - The company has faced setbacks, including the discontinuation of its lead candidate REC-994 and REC-2282 due to unfavorable efficacy results [6][8] - RXRX is focusing on developing candidates like REC-4881 for familial adenomatous polyposis, which has shown a preliminary median 43% reduction in polyp burden [8] - The company ended Q1 2025 with a cash balance of $509 million, expected to sustain operations into mid-2027 [9] - RXRX has collaboration agreements with major pharmaceutical companies, generating $15 million in collaboration revenues in Q1 2025, a slight increase from the previous year [10] Schrodinger (SDGR) - SDGR employs a physics-based computational platform for drug discovery, with its lead candidate SGR-1505 currently in a phase I study for B-cell malignancies [11][13] - The candidate has received FDA's Orphan Drug designation for mantle cell lymphoma [14] - SDGR's second candidate, SGR-2921, is being evaluated for acute myeloid leukemia, with initial results expected in the second half of 2025 [15] - The company generated $59.6 million in total revenues in Q1 2025, a 63% year-over-year increase [17] Financial Performance - RXRX's stock has declined 39.6% year-to-date, while SDGR's stock has increased by 10.9% [25] - RXRX trades at 1.78 times its book value, significantly lower than SDGR's 4.2 times, making RXRX more attractive from a valuation perspective [26][27] - The Zacks Consensus Estimate for RXRX's 2025 revenues implies a 22% year-over-year improvement, while SDGR's estimate suggests a 21% improvement but a widening loss per share [18][21] Market Position and Competitive Landscape - Both companies face competition from other biotech firms and tech-driven drug discovery companies, which may challenge their market differentiation [31] - Despite the competitive landscape, both RXRX and SDGR have the potential to revolutionize drug discovery by delivering cost-effective therapies [32] - RXRX is viewed as a better investment opportunity due to its innovative pipeline, collaboration agreements, and favorable valuation compared to SDGR [34]

Core Viewpoint - Renovaro Inc. has initiated legal action against Predictive Oncology Inc. to enforce a merger agreement, alleging breaches of contract and seeking specific performance and damages [1][4]. Group 1: Legal Proceedings - Renovaro filed a lawsuit on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology to enforce a merger agreement executed on January 1, 2025 [1]. - The court has ruled to expedite the trial for this lawsuit, which is pending under Case No. 2025-0509 [4]. - Renovaro claims that Predictive Oncology breached the agreement by conducting a public offering of $545,000 in securities on February 19, 2025, and later attempted to unilaterally terminate the agreement on April 3, 2025 [3]. Group 2: Financial Impact - Following the public disclosure of the merger agreement on January 6, 2025, Predictive Oncology's stock price increased by over 50% [2]. - The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches, indicating potential financial implications for both companies [4]. Group 3: Company Background - Renovaro Inc. focuses on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, aiming to accelerate precision and personalized medicine [5]. - The company includes subsidiaries such as RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, leveraging AI for diagnostics and drug development [5].

Core Viewpoint - Renovaro Inc. has initiated legal action against Predictive Oncology Inc. to enforce a merger agreement, alleging breaches of contract and seeking specific performance and damages [1][4]. Group 1: Legal Proceedings - Renovaro filed a lawsuit on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology to enforce a merger agreement executed on January 1, 2025 [1]. - The court has ruled to expedite the trial for this lawsuit, which is pending under Case No. 2025-0509 [4]. - Renovaro claims that Predictive Oncology breached the agreement by conducting a public offering of $545,000 in securities on February 19, 2025, and later attempted to unilaterally terminate the agreement [3]. Group 2: Financial Impact - Following the public disclosure of the merger agreement on January 6, 2025, Predictive Oncology's stock price increased by over 50% [2]. - The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches, indicating potential financial implications for both companies [4]. Group 3: Company Background - Renovaro Inc. focuses on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, aiming to accelerate precision and personalized medicine [5]. - The company includes subsidiaries such as RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, leveraging AI for diagnostics and drug development [5].

“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.”On Sequoia Capital’s Training Data podcast, our Chief AI Officer @MaxJaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines.Listen to the full podcast at the link below:https://t.co/0ve7jAAZxN ...

Summary of Schrödinger (SDGR) 2025 Conference Call Company Overview - Schrödinger combines physics-based methods with artificial intelligence (AI) and machine learning to accelerate the discovery of novel chemical materials for life sciences and material sciences applications [2][5] - The company has approximately 1,800 global customers, primarily in the life sciences sector, including nearly every academic institution studying chemistry [3][4] Financial Performance - In the previous year, Schrödinger reported $180 million in software revenue, growing at 13% [6] - Drug discovery revenue was $27 million, down from $57 million due to a large milestone payment in 2023 [7] - Q1 revenue reached nearly $60 million, a 63% year-over-year increase, with software revenue at $48.8 million (46% growth) and drug discovery revenue at $10.7 million [8][9] - The company forecasts total software revenue growth of 10% to 15% for the year, with drug discovery revenue expected to recover to $45 million to $50 million [9] Business Model and Revenue Streams - Schrödinger's business model includes software licensing, drug discovery collaborations, and a proprietary pipeline with over eight active programs, three of which are in clinical stages [5][6] - The company benefits from cash inflows from collaborations and equity investments in co-founded companies that have gone public or been acquired [8] Strategic Priorities - The focus is on increasing adoption of computational technology among existing customers rather than acquiring new customers [12] - Enhancements to the platform will enable its use for biologics and predicting toxicology risks, aligning with FDA initiatives to phase out animal testing [12][51] Clinical Programs and Pipeline - The company is advancing three proprietary clinical programs, with data readouts expected in the second half of the year [10][20] - Preliminary efficacy data for SGR1505, a MALT1 inhibitor, shows promising results in heavily pretreated patients [14][15] Collaborations and Partnerships - Recent collaborations include a significant deal with Novartis, which involved a $150 million upfront milestone payment for drug discovery collaboration [33] - The partnership with Novartis has led to a substantial increase in software revenue, with Novartis now among the top tier of customers [36][62] Market Dynamics and Customer Insights - The company has observed no significant cutbacks in R&D spending among large pharmaceutical companies despite macroeconomic challenges [60] - Retention rates among large customers are exceptionally high at 99.9% [61] Competitive Landscape - Schrödinger differentiates itself through its unique combination of physics-based methods and machine learning, with limited direct competition in this niche [72][74] - The company views the current AI boom in drug discovery as beneficial, as it may lead to increased use of structure-based drug design, which aligns with Schrödinger's platform [73][74] Conclusion - Schrödinger is well-positioned for growth with a robust business model, strong financial performance, and strategic collaborations, while also adapting to industry trends and regulatory changes in drug discovery and development.

Revolutionizing Medicines and Materials Discovery 1Q25 Financial Results May 7, 2025 Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schrödinger, Inc. ("we," "us," "our," "Schrödinger," or the "Company") contained in this presentation, including, without limitation, st ...